Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
This article was originally published in PharmAsia News
Executive Summary
Takeda is gearing up for a 2010 launch of the orphan bone cancer immunotherapy Mepact (mifamurtide) in Europe and is considering re-submitting its failed U.S. FDA application for that compound, after buying IDM Pharma for $75 million in a deal announced May 18